Health ministry asks DGCI to ensure equitable distribution of Remdesivir, Tocilizumab drugs

By: |
Published: July 29, 2020 6:03 PM

The aim is to ensure that their availability is not skewed and does not remain confined to metropolitan areas, an official said.

"I am directed to say that apart from availability, the geographical distribution/reach of the drugs included as part of investigational therapies in Clinical Management Protocols for COVID-19, namely Remdesivir and Tocilizumab, may also be monitored.“I am directed to say that apart from availability, the geographical distribution/reach of the drugs included as part of investigational therapies in Clinical Management Protocols for COVID-19, namely Remdesivir and Tocilizumab, may also be monitored.

The Union health ministry has asked the Drugs Controller General of India to ensure equitable distribution of Remdesivir and Tocilizumab drugs, which have been included as “investigational therapies” in the national treatment protocols for COVID-19, across the country.

The aim is to ensure that their availability is not skewed and does not remain confined to metropolitan areas, an official said.

The ministry has shot off a letter to the Drugs Controller General of India (DCGI), asking it to ascertain how many states and Union territories (UTs) have been covered and which of them are left, as far as the availability and distribution of these drugs by the respective companies is concerned.

“I am directed to say that apart from availability, the geographical distribution/reach of the drugs included as part of investigational therapies in Clinical Management Protocols for COVID-19, namely Remdesivir and Tocilizumab, may also be monitored.

“This ministry may kindly be apprised as to how many states and UTs have been covered and which of the states and UTs, if any, are left as far as the availability and distribution of these drugs by the respective companies is concerned,” the letter dated July 27 said.

The ministry has included the use of Remdesivir (for restricted emergency use purposes) and off-label application of Tocilizumab for treating COVID-19 patients in moderate stage of the illness as investigational therapies” in the updated Clinical Management Protocol for COVID-19.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Researchers identify 73 novel variants of COVID-19 strain in Odisha
2Coronavirus in India: 65,002 new cases take COVID-19 tally to 25.26 lakh; death toll rises to 49,036
374th Independence Day: PM Modi launches National Digital Health Mission, unique health ID for every citizen